Opinion - Why is cancer drug discovery so difficult?

被引：269

作者：

Kamb, Alexander

Wee, Susan

Lengauer, Christoph

机构：

[1] Novartis BioMed Res, Cambridge, MA 02139 USA

[2] Amgen Corp, San Francisco, CA 94010 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2007年 / 6卷 / 02期

关键词：

D O I：

10.1038/nrd2155

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Thirty-five years after the 'war on cancer' was declared, the discovery of anticancer drugs remains a highly challenging endeavour. Here, we consider the factors responsible, such as tumour heterogeneity, and suggest strategies to improve the chances of short-term success in the development of novel anticancer drugs.

引用

收藏

页码：115 / 120

页数：7

相关论文

共 33 条

[1]

Aghajanian C, 2002, CLIN CANCER RES, V8, P2505

[2] An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab [J].

Boye, J ;

Elter, T ;

Engert, A .

ANNALS OF ONCOLOGY, 2003, 14 (04) :520-535

[3] Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition [J].

Brown, P ;

Meshinchi, S ;

Levis, M ;

Alonzo, TA ;

Gerbing, R ;

Lange, B ;

Arceci, R ;

Small, D .

BLOOD, 2004, 104 (06) :1841-1849

[4] Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme [J].

Chang, SM ;

Wen, P ;

Cloughesy, T ;

Greenberg, H ;

Schiff, D ;

Conrad, C ;

Fink, K ;

Robins, HI ;

De Angelis, L ;

Raizer, J ;

Hess, K ;

Aldape, K ;

Lamborn, KR ;

Kuhn, J ;

Dancey, J ;

Prados, MD .

INVESTIGATIONAL NEW DRUGS, 2005, 23 (04) :357-361

[5] Strategies for optimizing combinations of molecularly targeted anticancer agents [J].

Dancey, Janet E. ;

Chen, Helen X. .

NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (08) :649-659

[6] Strategies to overcome resistance to targeted protein kinase inhibitors [J].

Daub, H ;

Specht, K ;

Ullrich, A .

NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (12) :1001-1010

[7] Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib [J].

Eberhard, DA ;

Johnson, BE ;

Amler, LC ;

Goddard, AD ;

Heldens, SL ;

Herbst, RS ;

Ince, WL ;

Jänne, PA ;

Januario, T ;

Johnson, DH ;

Klein, P ;

Miller, VA ;

Ostland, MA ;

Ramies, DA ;

Sebisanovic, D ;

Stinson, JA ;

Zhang, YR ;

Seshagiri, S ;

Hillan, KJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5900-5909

[8]

Ellis Lee M, 2005, Nat Rev Drug Discov, VSuppl, pS8

[9] Histone deacetylase inhibitors: A review of their clinical status as antineoplastic agents [J].

Garcia-Manero, G ;

Issa, JP .

CANCER INVESTIGATION, 2005, 23 (07) :635-642

[10]

Gardner SN, 2003, MOL CANCER THER, V2, P1079

← 1 2 3 4 →